Skip to main content
. 2023 Feb 24;11(6):240. doi: 10.21037/atm-22-3702

Table 2. Characteristics of the chest wall recurrences.

Clinical features, N=22 Patients with no axillary surgery, N=19, n (%) Patients with sentinel lymph node biopsy, N=2, n (%) Patients with axillary lymph node dissection, N=1, n (%) P value#
Age (years) at recurrence 0.0227
   <50 4 (21.1) 2 (100.0) 1 (100.0)
   ≥50 15 (78.9) 0 (0) 0 (0)
Axillary ultrasound imaging 0.260
   Normal 18 (94.7) 2 (100.0) 0 (0)
   Abnormal 0 (0) 0 (0) 0 (0)
   Not done 1 (5.3) 0 (0) 1 (100.0)
Pathological features of the recurrences
   Invasive tumour size (mm)1 0.364
    ≤20 11 (57.9) 1 (50.0) 0 (0)
    >20 to ≤50 4 (21.0) 1 (50.0) 1 (100.0)
    >50 1 (5.3) 0 (0) 0 (0)
    Not available 3 (15.8) 0 (0) 0 (0)
   Tumour histology 0.558
    Invasive ductal 15 (79.0) 2 (100.0) 0 (0)
    Invasive lobular 2 (10.5) 0 (0) 0 (0)
    Others2 2 (10.5) 0 (0) 1 (100.0)
   Grade 1.000
    I 3 (15.8) 0 (0) 0 (0)
    II 12 (63.1) 2 (100.0) 1 (100.0)
    III 3 (15.8) 0 (0) 0 (0)
    Not available 1 (5.3) 0 (0) 0 (0)
   ER 1.000
    Positive 17 (89.5) 2 (100.0) 1 (100.0)
    Negative 2 (10.5) 0 (0) 0 (0)
   PR 1.000
    Positive 14 (73.7) 2 (100.0) 1 (100.0)
    Negative 5 (26.3) 0 (0) 0 (0)
   HER2 1.000
    Positive 1 (5.3) 0 (0) 0 (0)
    Negative 18 (94.7) 2 (100.0) 1 (100.0)
   Pathological nodal involvement3 NA
    Yes NA 0 (0) 0 (0)
    No NA 2 (100.0) 1 (100.0)
   Chemotherapy 0.247
    Yes 5 (26.3) 2 (100.0) 0 (0)
    No 13 (68.4) 0 (0) 1 (100.0)
    Not available 1 (5.3) 0 (0) 0 (0)
   Radiotherapy 0.521
    Yes 11 (57.9) 2 (100.0) 1 (100.0)
    No 6 (31.6) 0 (0) 0 (0)
    Not available 2 (10.5) 0 (0) 0 (0)
   Hormonal therapy 1.000
    Yes 14 (73.7) 2 (100.0) 1 (100.0)
    No 3 (15.8) 0 (0) 0 (0)
    Not available 2 (10.5) 0 (0) 0 (0)
   Targeted HER2 therapy 1.000
    Yes 0 (0) 0 (0) 0 (0)
    No 19 (100.0) 2 (100.0) 1 (100.0)
   Axillary recurrence 1.000
    Yes 0 (0) 0 (0) 0 (0)
    No 19 (100.0) 2 (100.0) 1 (100.0)
   Second recurrence 1.000
    Yes 3 (15.8) 0 (0) 0(0)
    No 16 (84.2) 2(100.0) 1(100.0)

1, based on the largest invasive tumour size if multiple lesions present; 2, mucinous subtype; 3, based on the patients who underwent axillary surgery. #, Fisher’s exact test for patients with axillary surgery n=3 versus patients with no axillary surgery n=19. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; NA, not accessed.